Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative atezolizumab with or without tocilizumab in locally advanced head and neck squamous cell carcinoma
2018-000254-21Phase 2Terminated
- Sponsor
- Universitätsmedizin Essen
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and tocilizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: At least 2-fold increase in GzmB+/CD8+ T cells. Started Nov 2020; status: terminated.
02
Drugs
atezolizumabtocilizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2018-000254-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000254-21.